Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 6/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | GUSB | P08236 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5797396 | 0.89 | MAPK14 (0.47) | MAPK11MAPK14MAPK13MAPK12CYP2C9 | |
| SCHEMBL4240705 | 0.84 | LMNA (0.47) | MAPK11MAPK14MAPK13MAPK12CYP2C9 | |
| SCHEMBL5798754 | 0.81 | PIM1 (0.40) | MAPK11MAPK14MAPK13MAPK12CYP2C9 | |
| SCHEMBL4236899 | 0.77 | MAPK11 (0.44) | MAPK11MAPK14MAPK13MAPK12CYP2C9 | |
| SCHEMBL4247801 | 0.72 | MAPK11 (0.42) | MAPK11MAPK14MAPK13MAPK12CYP2C9 | |
| SCHEMBL2028562 | 0.71 | MAPK14 (0.41) | MAPK11MAPK14MAPK13MAPK12CYP2C9 | |
| SCHEMBL5796462 | 0.69 | MAPK14 (0.46) | MAPK11MAPK14MAPK13MAPK12CYP2C9 | |
| SCHEMBL6133646 | 0.67 | PTPN1 (0.39) | ALDH1A1 | |
| SCHEMBL4249675 | 0.67 | MAPK11 (0.40) | MAPK11MAPK14MAPK13MAPK12CYP2C9 | |
| SCHEMBL4240902 | 0.66 | AKR1B1 (0.45) | SMN1; SMN2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | ASTELLAS PHARMA INC (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1919919-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | Astellas Pharma Inc. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026950-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
| WO-2006038734-A1 | PYRIDAZINONE DERIVATIVES CYTOKINES INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | HRH2, OPRD1, HRH4 | MAPK11 1195/4885MAPK14 852/4885MAPK13 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.